Meeting
2022 ASCO Annual Meeting
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
Authors
Scott Kopetz
The University of Texas MD Anderson Cancer Center, Houston, TX
Scott Kopetz , Van K. Morris II, Bert O'Neil , John A. Bridgewater , Janet Graham , Eileen E. Parkes , Mark P. Saunders , Elspeth Asken , Louise Goodwin , Caroline Phillips , Jane Robertson , Craig Tilston , Simon Woodcock , Natalie Cook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04907539
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3637)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3637
Abstract #
TPS3637
Poster Bd #
426b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
First Author: Yasunobu Ishizuka
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
First Author: Joseph J. Sacco
Poster
2023 ASCO Annual Meeting
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
First Author: Yoshiaki Nagatani
Poster
2023 ASCO Annual Meeting
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.
First Author: Julie L. Koenig